Jeffrey Peterson, associate professor of cancer biology with the Breast Cancer Translational Research Disease Group at Fox Chase Cancer Center, received a $1.4 million grant from the U.S. Department of Defense to evaluate and exploit the mechanisms of inducing programmed cell death using polyunsaturated fatty acids in triple-negative breast cancer.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
